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(>5 years) distant relapse, indicating that disseminated tumour cells can reside
for prolonged periods of time as “dormant” single cells or non-productive
micrometastasis in distant sites. Despite late relapse being a common
occurrence in breast cancer, the mechanisms underlying the maintenance of
the dormant state and the subsequent escape from dormancy remain poorly
elucidated. This can be attributed to a lack of animal models, which can
recapitulate the natural progression to dormancy.
Material and Methods: In this study we have identiﬁed two human breast
cancer cell lines which either in a spontaneous metastasis setting or when
inoculated directly into the circulation, gives rise to dormant cells in the lungs
of immunocompromised mice. In addition to this we have established an in vitro
dormancy assay and an ex vivo lung slice approach in order to interrogate the
stromal factors identiﬁed from the in vitro and in vivo models, that are required
for the progression from a dormant state to a proliferative one.
Results and Discussion: In both the in vitro and in vivo models we have
demonstrated that these dormant cells can be stimulated to develop productive
macrometastasis. Using an ex vivo lung slice approach, we were able to
maintain viability of the lung slices for up to 21 days with the breast cancer cells
remaining dormant as seen in vivo. This provides a platform to strictly manipu-
late stromal factors and monitor the emergence from dormancy in live tissue.
Conclusion: Using these models we can interrogate the contribution of the
microenvironment to the emergence from metastatic dormancy with an overall
aim to identify and develop clinically relevant novel strategies to suppress or
prevent the development of metastatic disease.
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Rapidly accumulating laboratory and clinical research evidence indicates that
anthocyanins have anticancer activity and more intriguing, the evaluation
of bilberry anthocyanins as chemo-preventive agents is progressing. These
applications are collectively due to the anthocyanins up-regulating tumor
suppressor genes, inducing apoptosis in cancer cells, repairing and protecting
genomic DNA integrity, which is important in reducing age-associated oxidative
stress, as well as improving neuronal and cognitive brain function. Bilberry
anthocyanins have pronounced health effects, even though they have a low
bioavailability. To increase the bioavailability, Bilberry was encapsulated in
8 nm diameter liposomal nanospheres, called NutraNanoSpheres (NNS), at
a concentration of 2.5mg/50 mL. These Bilberry NNS were used to study the
apoptotic/cytotoxic effects on K562 cancer cells. Flow cytometric ﬂuorescent
quantiﬁcation of the uptake of Propidium Iodide in a special cell viability
formulation into dead K562 cells was used to determine the effects of Bilberry
on the viability of K562 cells. The concentrations of Bilberry that showed
the highest levels of percentage inhibition, relative to the control populations,
were biphasic, showing 60−70% inhibition between 0.018–1.14mg/ml (n = 6)
and 60% inhibition at 80mg/ml. The lowest % inhibition (30%) occurred at
40mg/ml. The LD50 was determined to be 0.01–0.04mg/ml of Bilberry per
105 K562 cells at 72 hr. of cell culture exposure. At 48 hr. incubation, the
highest % inhibition was only 27%, suggesting a long-term apoptotic event
being involved. These levels, which showed direct cytotoxic effects, were 10
times lower than what is required for the Bilberry that is not encapsulated. The
10 fold increase in bioavailability with the Bilberry NNS and its water solubility
show the feasibility of using Bilberry NNS in cancer patient clinical trials.
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Background: Chronic inﬂammation is a hallmark of most, if not all cancers
and is a major risk factor in the development of many cancer types. Immune
cells create a microenvironment that promotes the survival and sustained
proliferation of cancer cells as well as encouraging malignant transformation,
angiogenesis and resistance to therapy. Consequently, it is vital to develop a
pre-clinical model in which we can assess tumour-related inﬂammation and
correlate this with disease progression and therapeutic response. To address
this need we are developing the two-stage carcinogenesis model, for use in
pre-clinical PET and MR-imaging. In this model, heterogeneous tumours with
complex microenvironments develop in situ, in immune-competent animals.
Metastatic progression to invasive squamous cell carcinoma (SCC) occurs in
10−15% of tumours, permitting the assessment of malignant transformation
in the context of an intact immune system. Because the model generates
multiple tumours, the effects of different topically applied treatments can be
evaluated on the same animal, enabling efﬁcient pharmacodynamic biomarker
validation. Treatment of these tumours with an established pharmacological
inhibitor (XMD8-92) of the fundamental cell-signalling protein ERK5, decreases
intra-tumoural inﬂammation (particularly macrophages) eliciting a substantive
decrease in tumour burden.
Materials and Methods: Anti-ERK5 therapy (XMD8-92) was employed as a
tool to modify the inﬂammatory tumour microenvironment. We then evaluated
the effect of XMD8-92 on intra-tumoural inﬂammation using the PET tracers
[11C]PK11195 and [18F]FDG. We also employed DW-MRI (ADC) to evaluate
changes in cellularity in order to determine if this technique can detect changes
in tumour immune cell inﬁltrate.
Results: Inhibition of intra-tumoural inﬂammation, via anti-ERK5 therapy,
resulted in a reduction in tumour-associated uptake of [11C]PK11195
and [18F]FDG. Diffusion-weighted MRI revealed that control tumours show
increases in ADC over time, consistent with a change in cellularity that may
reﬂect inﬂammation. XMD8-92-treated tumours show stabilisation of ADC
relative to control.
Conclusions: The TSPO-based PET tracer [11C]PK11195 can track speciﬁc
changes in intra-tumoural macrophage populations. Anti-ERK5 therapy may
also alter tumour glucose consumption. DW-MRI can give rise to biomarkers
indicative of inﬂammation.
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Background: Lysyl oxidase (LOX), an extracellular matrix remodelling
enzyme, has a role in normal embryonic development and connective
tissue function. However, LOX promotes tumour progression and metastases
although it may also have tumour-inhibitory effects, which depend on the
location and the transformation status of the tumour, and the cell type involved.
Our previous studies found higher expressions of LOX in clear cell renal cell
carcinoma (ccRCC) compared to adjacent normal renal tissues. Clear cell
renal cell carcinoma arise from epithelial cells of the proximal convoluted
tubules of the nephron and account for approximately 80% of all renal
malignancies. Unfortunately, the link between LOX activity and ccRCC cell
adhesion and metastasis remains unclear.
Material and Methods: ccRCC cell line, Caki-2 cells were cultured in McCoy’s
5A complete growth medium supplemented with 10% FBS in a humidiﬁed
5% CO2 atmosphere at 37 ºC. Various concentrations (50 to 200 mM) of
beta-aminopropionitrile (BAPN), an irreversible inhibitor of LOX, were used
to inhibit LOX activity in ccRCC cells for 24 to 48 hours in vitro. Untreated
cells cultured under the same condition were used as control. The activities
of LOX were tested using a ﬂuorometric method. BAPN treated and untreated
cells adhesion to ﬁbronectin were analyzed. The expression of genes involved
in tumour metastatic signalling pathways were assessed by quantitative RT-
PCR. Western blotting analyses were performed to evaluate the expressions
of matrix metalloproteinases, MMP2 and MMP9, following LOX inhibition in
Caki-2 cells.
Results and Discussion:Our results showed that BAPN inhibited LOX activity
in ccRCC cells in a dose-dependent manner in vitro. LOX inhibition was
associated with a signiﬁcant increase in ccRCC cell adhesion to ﬁbronectin
in vitro. The inhibition of LOX enzyme elevated the expression of metastatic
regulatory genes, MTSS1 and NME in ccRCC cells. In contrast, expressions of
MMP2 and MMP9 proteins in ccRCC were reduced following LOX inhibition.
These results indicate that LOX may promote ccRCC cell progression and
metastasis by modulating metastatic gene expressions. Thus, targeting LOX by
inhibiting its activity may be a new strategy in preventing ccRCC metastasis.
Conclusion: LOX activity affects ccRCC cell adhesion to extracellular matrix,
and is associated with cancer cell metastasis. This study suggests LOX may
be a potential therapeutic target in ccRCC patients.
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Introduction: GRP94 is a 94-kDa glycoprotein abundant in the endoplasmic
reticulum (ER) and is induced by glucose starvation. Overexpression of GRP94
